The evidence in support of genetic-based dosing of coumarin anticoagulant drugs such as warfarin is mixed at best, based on the results of three studies published in The New England Journal of Medicine Nov. 19.
Warfarin (marketed by Bristol-Myers Squibb Co.under the name Coumadin),a vitamin K antagonist, is commonly used by cardiologists as an oral anticoagulant agent. But dosing of the drug is tricky...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?